Effectiveness of sodium-glucose cotransporter 2 inhibitors in patients with metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomized controlled trials
{{output}}
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent and can progress to cirrhosis and hepatocellular carcinoma. Treatment options are still lacking. We assessed the efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i)... ...
